[Ip-health] MSF response to UNSG HLP on Access to Meds report

Joanna Keenan joanna.l.keenan at gmail.com
Wed Sep 14 08:18:15 PDT 2016

Hi all

In response to the UN SG HLP's report on Access to Medicines released
today, Médecins Sans Frontières (MSF) has issued the below response:


On 14 September, The United Nations Secretary-General’s High-Level Panel
(UNHLP) on Access to Medicines will publish a landmark report on promoting
innovation for, and access to, health technologies.

The UNHLP’s report outlines in detail the global failure of the medical
research system to develop medicines, vaccines and diagnostics that address
unmet medical needs affecting communities across the globe, and puts forth
recommendations aimed at making health technologies affordable and
available to all in need.

MSF welcomes the panel’s recommendations on the need for new incentives for
research and development, for greater transparency, as well as for
strategies to deal with intellectual property barriers, all with the aim of
improving medical innovation and access to health technologies.

MSF strongly urges the UN Secretary General, governments and industry to
act upon these recommendations with the urgency that public health demands.

MSF responds to the UN Secretary General’s High-Level Panel on Access to
Medicines report:
“MSF welcomes the landmark report from the UN Secretary-General’s
High-Level Panel on Access to Medicines, which puts forth actionable
recommendations to help overcome the challenges that our medical teams have
faced for decades – being left essentially empty-handed when the medicines,
vaccines and diagnostics we need for our patients don’t exist, or are too
expensive.  The report’s global scope recognizes that today all countries
face challenges in ensuring availability and affordable access to the
medical tools that people need to live healthy and productive lives.

"MSF urges governments and industry to rapidly implement the
recommendations of the High-Level Panel’s report, including demanding more
transparency from pharmaceutical corporations on research and development
costs and prices, breaking the link between the way research and
development is funded and how much companies charge for lifesaving medical
tools, and minimising existing barriers, in particular intellectual
property-backed monopolies, that undermine access to affordable medicines
and vaccines.

"The report should serve as a call to action for the UN Secretary General
and governments attending the UN General Assembly this week as they work to
find global solutions to combat drug-resistant infections:  it’s time for
governments to implement policies and incentives that will promote
health-driven innovation and improve access for people in need no matter
where they live.  Governments must go beyond the challenge of
drug-resistant infections and make bold, broad reforms in the way medical
research and development is conducted, so we can stop failing humanity on
such a basic need.”

- Rohit Malpani, Director of Policy and Analysis, MSF Access Campaign

To read MSF’s report on medical research and development, visit

*Joanna Keenan*
Press Officer
Médecins Sans Frontières - Access Campaign
P: +41 22 849 87 45
M: +41 79 203 13 02
E: joanna.keenan[at]geneva.msf.org
T: @joanna_keenan


More information about the Ip-health mailing list